Literature DB >> 20026050

Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation.

Elisa A Waxman1, Kristel L Emmer, Benoit I Giasson.   

Abstract

Alpha-synuclein (alpha-syn) amyloid filaments are the major ultrastructural component of pathological inclusions that define several neurodegenerative disorders, including Parkinson disease and other disorders that are collectively termed synucleinopathies. Since the aggregation of alpha-syn is associated with the etiology of these diseases, defining the molecular elements that influence this process may have important therapeutics implication. The deletions of major portions of the hydrophobic region of alpha-syn (Delta74-79 and Delta71-82) impair the ability to form amyloid. However, mutating residue E83 to an A restored the ability of these proteins to form amyloid. Additionally supporting an inhibitory role of residue E83 on amyloid formation, mutating this residue to an A enhanced amyloid formation in the presence of small molecule inhibitors, such as dopamine and EGCG. Our data, therefore, suggest that the presence and placement of the highly charged E83 residue plays a significant inhibitory role in alpha-syn amyloid formation and these findings provide important insights in the planning of therapeutic agents that may be capable of preventing alpha-syn amyloid formation. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20026050      PMCID: PMC2812690          DOI: 10.1016/j.bbrc.2009.12.079

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  58 in total

Review 1.  Conformational constraints for amyloid fibrillation: the importance of being unfolded.

Authors:  Vladimir N Uversky; Anthony L Fink
Journal:  Biochim Biophys Acta       Date:  2004-05-06

2.  Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

3.  Prediction of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

4.  X-ray diffraction studies on amyloid filaments.

Authors:  E D Eanes; G G Glenner
Journal:  J Histochem Cytochem       Date:  1968-11       Impact factor: 2.479

Review 5.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

6.  Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.

Authors:  Woong Choi; Shahin Zibaee; Ross Jakes; Louise C Serpell; Bazbek Davletov; R Anthony Crowther; Michel Goedert
Journal:  FEBS Lett       Date:  2004-10-22       Impact factor: 4.124

7.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; N J Cairns; P L Lantos; M Goedert
Journal:  Neurosci Lett       Date:  1998-07-31       Impact factor: 3.046

8.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease.

Authors:  Marie-Christine Chartier-Harlin; Jennifer Kachergus; Christophe Roumier; Vincent Mouroux; Xavier Douay; Sarah Lincoln; Clotilde Levecque; Lydie Larvor; Joris Andrieux; Mary Hulihan; Nawal Waucquier; Luc Defebvre; Philippe Amouyel; Matthew Farrer; Alain Destée
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

9.  Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1.

Authors:  H Naiki; K Higuchi; M Hosokawa; T Takeda
Journal:  Anal Biochem       Date:  1989-03       Impact factor: 3.365

10.  The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils.

Authors:  Min Zhu; Sudha Rajamani; Joanna Kaylor; Shubo Han; Feimeng Zhou; Anthony L Fink
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

View more
  6 in total

1.  Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Authors:  Kevin H Strang; Cara L Croft; Zachary A Sorrentino; Paramita Chakrabarty; Todd E Golde; Benoit I Giasson
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

2.  Countering amyloid polymorphism and drug resistance with minimal drug cocktails.

Authors:  Martin L Duennwald; James Shorter
Journal:  Prion       Date:  2010-10-12       Impact factor: 3.931

3.  α-Synuclein arginylation in the human brain.

Authors:  Jun Zhao; Buyan Pan; Marie Fina; Yun Huang; Marie Shimogawa; Kelvin C Luk; Elizabeth Rhoades; E James Petersson; Dawei W Dong; Anna Kashina
Journal:  Transl Neurodegener       Date:  2022-04-08       Impact factor: 8.014

4.  A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity.

Authors:  Senthil T Kumar; Anne-Laure Mahul-Mellier; Ramanath Narayana Hegde; Gwladys Rivière; Rani Moons; Alain Ibáñez de Opakua; Pedro Magalhães; Iman Rostami; Sonia Donzelli; Frank Sobott; Markus Zweckstetter; Hilal A Lashuel
Journal:  Sci Adv       Date:  2022-04-29       Impact factor: 14.957

Review 5.  Nutraceuticals in Parkinson's Disease.

Authors:  Liting Hang; Adeline Henry Basil; Kah-Leong Lim
Journal:  Neuromolecular Med       Date:  2016-05-04       Impact factor: 3.843

6.  Protein arginylation targets alpha synuclein, facilitates normal brain health, and prevents neurodegeneration.

Authors:  Junling Wang; Xuemei Han; Nicolae Adrian Leu; Stephanie Sterling; Satoshi Kurosaka; Marie Fina; Virginia M Lee; Dawei W Dong; John R Yates; Anna Kashina
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.